AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Scientists at University of Barcelona publish new data on HIV/AIDS
June 15th, 2009
In this recent report, researchers in Barcelona, Spain conducted a study "To evaluate the efficacy and safety of switching from boosted lopinavir (LPV/r) to boosted atazanavir (ATV/r) in virologically suppressed HIV-1-infected patients versus continuing LPV/r. Forty-eight weeks analysis of a randomized, open-label, noninferiority trial including patients with virological suppression (<= 200 copies/mL for >= 6 months) on LPV/r-containing triple highly active antiretroviral therapy." "Patients (n = 248) were randomized 1:1 either to continue LPV/r twice a day (n = 127) or to switch to ATV/r every day (ATV/r; n = 121), with no change in nucleoside reverse...
Source: AIDS Weekly (2009-06-15)
|
